September 30, 2016 5:29pm
… As the session opened barely positive after yesterday's pullback and strengthens from there on …
Having stated a rebound was in the cards in the pre-open and “it’s time to bite or nibble even for a Friday”; the iShares Nasdaq Biotechnology ETF (IBB) advanced 1.26%
Pre-open indication’s tally: 11 hits <ADRO, AGTC, AST, BLCM, BLUE, CLBS, CLLS, JUNO, MESO, ONCE and VSTM > and 1 miss < KITE>
I answer one question; in which company should investors put, keep and commit their money!
Do you care what happened today, you should because it has implications to Monday's sector activity?
Subscribe or lose!
I say what others won't, so you can do what others can't!
There are two things that investors need - interpretation of news and translation of market metrics concerning the stem, cell, gene and regenerative therapy sector to substantiate share pricing.
U.S. equities close sharply higher on Friday as Deutsche Bank shares rebounded amid a report that the German banking giant was near a settlement with the Justice Department.
The NASDAQ closed UP +42.85 or +0.81% to 5,312.00 and the DOW closed UP +164.70 or +0.91% to 18,308.15.
A day in the life of the stem, cell, gene and regenerative therapy (SCGT & RT) sector – the advance/decline line scenario of our 43 covered companies:
- The open was barely positive with an A/DL of 21/20 and 2 flats;
- The mid-day stayed positive with an A/DL of 29/11 and 3 flats;
- The closing bell stayed positive with A/DL of 29/12 and 2 flats;
Henry’omics:
The stem, cell, gene and regenerative therapy (SCGT&RT) sector opened barely positive, stayed positive at the mid-day with the sector closing positive.
I keep telling investors in the a.m. to check the indexes:
- The iShares Russell 2000 (IWM) was NOT indicating in the pre-open and was UP +1.10% at the close while the iShares Nasdaq Biotechnology (IBB) did NOT indicate in the pre-open and closed UP +1.26% at the close.
Look at today, technicals and fundamentals matter yet they seem over-ridden:
- The downside reflects a range of -0.21% to -$2.94% on Friday of xx equities compared to Thursday’s – 0.31% to -6.02% of 35 equities versus Wednesday’s -0.23% to -7.93% in 27 decliners;
- The upside shows a range of +0.04% to +6.27% in 29 equities as compared to Thursday’s 7 positive close equities of +0.30% to $2.96% versus Wednesday’s 13 advancers with a variance of +0.34% to +5.10% - percentage is a factor in a day;
Pre-open <prognostication> indication’s tally: 11 hits and 1 miss:
- Aduro Biotech (ADRO) closed UP +$0.39 – hit;
- Applied Genetic Technologies (AGTC) closed DOWN -$0.10 – hit;
- Asterias Biotherapeutics (NYSEMKT: AST) closed UP +$0.05 - hit;
- Bellicum Pharma (BLCM) closed UP +$0.03 - hit;
- bluebird bio (BLUE) closed UP +$1.37 - hit;
- Caladrius Biosciences (CLBS) closed DOWN -$0.14 – hit;
- Cellectis SA (CLLS) closed UP +$0.01 - hit;
- Juno Therapeutics (JUNO) closed UP +$0.02 - hit;
- Kite Pharma (KITE) closed DOWN -$0.12 - miss;
- Mesoblast (MESO) closed UP +$0.13 - hit;
- Spark Therapeutics (ONCE) closed UP +$1.66 - hit;
- Verastem (VSTM) closed UP +$0.01 - hit
Percentage decliners:
- Caladrius Biosciences (CLBS) -2.94%;
- Northwest Bio (NWBO) -1.75%;
- VistaGen (VTGN) -2.58%;
- Vericel (VCEL) -1.75%;
- Histogenics (HSGX) -1.86% after Thursday’s +1.58%;
Percentage advancers:
- BioTime (NYSEMKT: BTX) +6.27%;
- Stemline (STML) +5.66%;
- Osiris (OSIR) +5.53%;
- Fate Therapeutics (FATE) +3.31%;
- Aduro Biotech (ADRO) +3.24% after Thursday’s -7.60%
Flat:
- International Stem Cell (ISCO) at $1.85;
Volume movers – WATCH the numbers:
- Volume remains to the LOW side except in AST, RENE.L’s downside and ATHX’s and BSTG’s upside;
- A favorite “spot” to be in these days is FLAT – ISCO is than a splat …
- Other downside views are Caladrius Biosciences (CLBS) volume <4416 shares> versus 3 month average of 36.178 shares;
- Volume jumped in ReNeuron (RENE.L) 4.774 M shares versus the 3 month average of 2.34 M shares still remaining or closing FLAT;
- Higher volume in Kite Pharma (KITE) 1.096 M share s traded <3 month average = 945 K shares;
- Volume traded with the 3 month average - AGTC although it dumped -$0.11 with 171 K shares traded <3 month average = 171.7 K shares>;
- Another downside views are Caladrius Biosciences’ (CLBS) dumped -$0.12 with volume <14.4 K shares> versus 3 month average of 36.1 K shares;
- Biostage (BSTG) also fell -$0.01 to $1.07 with 43.1 K shares traded <3 month average = 119.9 K shares>;
- BLFS jumped +1.10% or +$0.03 to $1.84 on 18.9 K shares <3 month average = 430.48 K shares>;
- Fate Therapeutics (FATE) jumped +$0.10 with 127.4 K shares traded <3 month average = 288.5 K shares>;
- Cellectis SA (CLLS) jumped +$0.16 to $24.23 with 68.9 K shares traded <3 month average = 90.19 K shares;
- Capricor’s (CAPR) higher volume <38.7 K shares> versus 3 month average volume <26,5 K shares>,
- Mesoblast (MESO) jumped +$0.13 to $4.31 with low 5522 shares traded <3 month average = 25.5 K shares>;
Review my fear gauge or the CBOE Volatility Index (VIX):
- Friday traded near 13.3, -5.2% lower;
- Thursday traded near 14.28 – a 15% jump;
- Wednesday traded near 12.4;
- Tuesday traded near 13.2;
- Monday traded near 14.3 -16.5% higher;
- Last Friday traded near 12.2 – I still don’t see it in our universe;
My pet peeve:
High-frequency trading accounted for 52% of September's daily trading volume of about 7.04 billion shares <TABB Group>
- During the peak levels of high-frequency trading in 2009, about 61%of 9.8 billion of average daily shares traded were executed by high-frequency traders.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
